InfuSystem (NYSEAMERICAN:INFU) Upgraded to “Strong-Buy” by StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a buy rating to a strong-buy rating in a report released on Wednesday.

InfuSystem Stock Performance

INFU opened at $7.87 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.95 and a quick ratio of 1.54. InfuSystem has a 12 month low of $7.75 and a 12 month high of $11.44. The firm has a market capitalization of $167.32 million, a P/E ratio of 262.42 and a beta of 1.24.

Hedge Funds Weigh In On InfuSystem

Large investors have recently modified their holdings of the business. Barclays PLC bought a new position in shares of InfuSystem during the second quarter worth approximately $35,000. BNP Paribas Arbitrage SNC increased its stake in InfuSystem by 3,895.0% in the second quarter. BNP Paribas Arbitrage SNC now owns 4,834 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 4,713 shares during the last quarter. Bank of America Corp DE increased its stake in InfuSystem by 31.3% in the first quarter. Bank of America Corp DE now owns 6,398 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 1,526 shares during the last quarter. California State Teachers Retirement System bought a new position in InfuSystem in the second quarter valued at approximately $58,000. Finally, UBS Group AG increased its stake in InfuSystem by 52.4% in the fourth quarter. UBS Group AG now owns 7,672 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 2,637 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors and hedge funds.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.